Skip to Content

Ruxolitinib

In the US, Ruxolitinib (ruxolitinib systemic) is a member of the drug class multikinase inhibitors and is used to treat Myelofibrosis, Myeloproliferative Disorders and Polycythemia Vera.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XE18

CAS registry number (Chemical Abstracts Service)

0941678-49-5

Chemical Formula

C17-H18-N6

Molecular Weight

306

Therapeutic Categories

Antipsoriatic

Antineoplastic agent

Chemical Name

(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile (WHO)

Foreign Names

  • Ruxolitinibum (Latin)
  • Ruxolitinib (German)
  • Ruxolitinib (French)
  • Ruxolitinib (Spanish)

Generic Names

  • Ruxolitinib (OS: USAN, BAN)
  • INC-424 (IS)
  • INCB 018424 (IS)
  • UNII-82S8X8XX8H (IS)
  • Ruxolitinib Phosphate (OS: USAN, JAN, BANM)
  • INCB018424 salt (IS)
  • UNII-436LRU32H5 (IS)

Brand Names

  • Jakavi
    Novartis, Bosnia & Herzegowina; Novartis, Finland; Novartis, Hungary; Novartis, Lithuania; Novartis, Latvia; Novartis, Norway; Novartis, Poland; Novartis, Slovakia; Novartis Farma, Italy; Orifarm, Norway
  • Jakafi
    Incyte, United States
  • Jakavi
    Novartis, Belgium; Novartis, Chile; Novartis, Denmark; Novartis, France; Novartis, Hong Kong; Novartis, Croatia (Hrvatska); Novartis, Ireland; Novartis, Israel; Novartis, Iceland; Novartis, South Korea; Novartis, Sweden; Novartis, Thailand; Novartis Europharm, Austria; Novartis Europharm, Slovenia; Novartis Farmaceutica, Spain; Novartis Pharma, Switzerland; Novartis Pharma, Germany; Novartis Pharma, Russian Federation; Novartis Pharmaceuticals, Canada; Novartis Pharmaceuticals UK, United Kingdom

International Drug Name Search

Glossary

TermDefinition
BANBritish Approved Name
BANMBritish Approved Name (Modified)
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide